Table 3.
Summary quality assessment of included studies
| Quality criterion | Studies (n, %) | ||
|---|---|---|---|
| Yes | No | Unclear | |
| Economic component | |||
| Data sources for expenditure, resource use and unit costs were clearly explained | 48 (58%) | 34 (42%) | n/a |
| Cost and/or productivity data were transparently presented | 24 (29%) | 59 (71%) | n/a |
| Productivity costs were included | 23 (28%) | 60 (72%) | 0 (0%) |
| If productivity costs included, results were presented with and without productivity costs | 20 (24%) | 3 (4%) | n/a |
| The analysis addressed uncertainty and/or heterogeneity | 53 (64%) | 30 (36%) | 0 (0%) |
| Epidemiologic component | |||
| The source of incidence/prevalence data contributed to the study’s internal validity | 35 (42%) | 13 (16%) | 28 (34%) |
| The patient sampling method appropriate for deriving nationwide estimates of incidence/prevalence | 21 (25%) | 49 (58%) | 9 (11%) |
Total number of studies does not add to n = 83 in all criteria because certain criteria were not applicable in several studies. Please see the Additional file containing the extraction sheet. n/a - not applicable